Read Full Article from CURE TODAY
FDA approval of Tepylute provides a ready-to-dilute thiotepa formulation for breast and ovarian cancer treatment, enhancing convenience and reducing preparation errors.
The new formulation eliminates the need for reconstitution, saving time and offering more scheduling flexibility for healthcare providers.